Market Introduction
Brain cancers are caused due to extracellular growth of the cells in the brain that causes tumors. The tumor includes primary brain tumors and secondary brain tumors. Primary brain tumors are formed in the brain and do not spread to other body parts, whereas secondary tumors, also known as metastases, are those cancers that began in another part of the body. Brain tumors are categorized into 40 major types that are further classified into two major groups, including benign, i.e., slow-growing and have less possibility to spread, and malignant, i.e., cancerous, and more likely to spread.
Thus, the increase in prevalence of brain cancer is expected to create a significant demand for brain cancer diagnostics in the coming years, which is further anticipated to drive the brain cancer diagnostics market.
The pandemic has caused disruptions to health services worldwide and has impacted the ability of countries to address and respond to critical conditions like brain cancer. In many countries, diagnostics services have been disrupted, and supply chains for key commodities have been stretched. In Africa, COVID-19 has threatened the control of major health conditions including brain cancer. As COVID-19 continues to spread in Africa, there are concerns over its impact on market, limited diagnosis, and decreased access to expert neurosurgeons further impacting the market in the region. However, as the pandemic situation overcomes, the demand for several diagnostics modalities used in brain cancer diagnosis will increase.
Market Overview and Dynamics
The Brain cancer diagnostics market in Middle East and Africa is expected to grow from US$ 87.4 million in 2021 to US$ 237.0 million by 2028; it is estimated to grow at a CAGR of 15.3% from 2021 to 2028. The term "primary brain tumor" refers to a tumor that begins in the brain. Cancer of the brain and nervous system is the tenth highest cause of mortality in men and women. In a person's lifetime, the chances of having this form of tumor are fewer than 1%. Most primary central nervous system (CNS) malignancies are brain tumors, which account for 85% to 90% of all cases. Brain tumors can be fatal, have a severe impact on quality of life, and ultimately transform a patient's and their family's lives. Furthermore, early detection of tumors often provides more treatment options. Advanced imaging technology can pinpoint the location of brain tumors. Diagnostic tools include magnetic resonance imaging (MRI) and computed tomography (CT or CAT scan). Intraoperative MRI can also be used to guide tissue biopsy and tumor resection during surgery. Magnetic resonance spectroscopy (MRS) is used to examine the chemical characteristics of tumors. Thus, the increase in the prevalence of brain cancer highly demands brain cancer diagnostic tools.
Key Market Segments
In terms of diagnostic type, the imaging test segment accounted for the largest share of the Middle East and Africa brain cancer diagnostics market in 2020. In terms of cancer type, the glioblastoma multiforme segment accounted for the largest share of the Middle East and Africa brain cancer diagnostics market in 2020. In terms of end user, the hospitals segment accounted for the largest share of the Middle East and Africa brain cancer diagnostics market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the brain cancer diagnostics market in Middle East and Africa are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Thermo Fisher Scientific Inc., Siemens Healthineers A, GE Healthcare, Biocept, Inc., Koninklijke Philips N.V, Canon Medical Systems, Hitachi, Ltd., and Neusoft Medical Systems.
Reasons to buy report
- To understand the Middle East and Africa Brain cancer diagnostics market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for Middle East and Africa Brain cancer diagnostics market
- Efficiently plan M&A and partnership deals in Middle East and Africa Brain cancer diagnostics market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Middle East and Africa Brain cancer diagnostics market
- Obtain market revenue forecast for market by various segments from 2021-2028 in Middle East and Africa region.
Middle East and Africa Brain Cancer Diagnostics Market Segmentation
By Diagnostic Type
- Imaging Test
- MRI
- CT Scan
- PET
- Biopsy
- Molecular Testing
- Lumbar Puncture
- Others
By Cancer Type
- Glioblastoma Multiforme
- Astrocytomas
- Ependymomas
- Others
By End User
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others
By Country
-
Middle East and Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of Middle East and Africa
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Siemens Healthineers A
- GE Healthcare
- Biocept, Inc.
- Koninklijke Philips N.V
- Canon Medical Systems
- Hitachi, Ltd.
- Neusoft Medical Systems
Middle East and Africa Brain Cancer Diagnostics Market Strategic Insights
Middle East and Africa Brain Cancer Diagnostics Market Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$ 87.4 Million |
| Market Size by 2028 | US$ 237.0 Million |
| CAGR (2021 - 2028) | 15.3% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Diagnostic Type
|
|
Regions and Countries Covered
|
|
| Middle East and Africa | South Africa, Saudi Arabia, UAE, Rest of Middle East and Africa |
| Market leaders and key company profiles |
|
Middle East and Africa Brain Cancer Diagnostics Market Country and Regional Insights
